BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study
Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective stu...
Saved in:
Published in | Annals of internal medicine Vol. 101; no. 4; p. 447 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.10.1984
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective study. Two hundred ninety-three patients were evaluable in the induction phase of this study. The complete remission rate with BCVPP was 76% (112/147) and with MOPP, 73% (106/146) (p = 0.51). The duration of complete remissions for previously untreated patients given BCVPP was significantly longer than that for previously untreated patients given MOPP (p = 0.02). Although hematologic toxicities were similar, BCVPP caused less gastrointestinal (p = 0.0001) and neurologic toxicity (p = 0.01) than MOPP. Previously untreated patients achieving complete remission with BCVPP survived significantly longer than those receiving MOPP (p = 0.03). As primary induction chemotherapy for advanced Hodgkin's disease, BCVPP is an effective alternative to MOPP, having equal or greater therapeutic benefit with less toxicity. |
---|---|
AbstractList | Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective study. Two hundred ninety-three patients were evaluable in the induction phase of this study. The complete remission rate with BCVPP was 76% (112/147) and with MOPP, 73% (106/146) (p = 0.51). The duration of complete remissions for previously untreated patients given BCVPP was significantly longer than that for previously untreated patients given MOPP (p = 0.02). Although hematologic toxicities were similar, BCVPP caused less gastrointestinal (p = 0.0001) and neurologic toxicity (p = 0.01) than MOPP. Previously untreated patients achieving complete remission with BCVPP survived significantly longer than those receiving MOPP (p = 0.03). As primary induction chemotherapy for advanced Hodgkin's disease, BCVPP is an effective alternative to MOPP, having equal or greater therapeutic benefit with less toxicity. |
Author | Glick, J H DeVita, Jr, V T Costello, W Berard, C W Anderson, J R Bakemeier, R F Horton, J Hines, J D Rosner, G |
Author_xml | – sequence: 1 givenname: R F surname: Bakemeier fullname: Bakemeier, R F – sequence: 2 givenname: J R surname: Anderson fullname: Anderson, J R – sequence: 3 givenname: W surname: Costello fullname: Costello, W – sequence: 4 givenname: G surname: Rosner fullname: Rosner, G – sequence: 5 givenname: J surname: Horton fullname: Horton, J – sequence: 6 givenname: J H surname: Glick fullname: Glick, J H – sequence: 7 givenname: J D surname: Hines fullname: Hines, J D – sequence: 8 givenname: C W surname: Berard fullname: Berard, C W – sequence: 9 givenname: V T surname: DeVita, Jr fullname: DeVita, Jr, V T |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/6089632$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kM1O5DAQhH1gxd_yBAipb1wI2J6QH27saBaQQINWiCtq2z0zhsSObCe7edh9FzKAOLX6q1J1qQ_YjvOOGDsW_LycyeKCcz7L8krUmeAiy7M8L3fY_jfdYwcxvm7XSla7bLfgVV3M5D77_2v-_PgIekOtTxsK2I2w8gHQDOg0Gbj1Zv1m3WkEYyNhpCugwRqaxA_jOhAmCmD6gMl6B34F2rddQ4kgUGtjnOjZty_2YbADNmeAzkBDMULy_6y2aYS0QQd_bdoAwsNyqhVobVty5_CHYt-kuA2fWsIC45TlYO59R9u7A8HSad_49Qg3wfcdxNSb8Sf7scIm0tHXPGRPvxdP89vsfnlzN7--z7So85TpqpRGFhyVKIymfKXkJWJZa13mUkkzUVVVxEVZ6hlXiqq8VrWQBpW5JCEP2clnbNerlsxLF2yLYXz5-rJ8B08EhSk |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.7326/0003-4819-101-4-447 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
ExternalDocumentID | 6089632 |
Genre | Research Support, U.S. Gov't, P.H.S Comparative Study Clinical Trial Randomized Controlled Trial Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA 23318 – fundername: NCI NIH HHS grantid: CA 11083 – fundername: NCI NIH HHS grantid: CA 21115 |
GroupedDBID | --- ..I .55 .GJ .XZ 08G 1CY 23M 2WC 354 36B 39C 3O- 3V. 4.4 53G 5GY 5RE 5RS 6J9 7RV 7X7 88E 8C1 8F7 8FI 8FJ 8G5 8R4 8R5 AAKAS AAQOH AAQQT AARDX AAWTL AAYOK ABBLC ABCQX ABJNI ABOCM ABPMR ABUWG ACBNA ACGFO ACGFS ADBBV ADZCM AEGXH AENEX AERZD AFCHL AFFNX AFKRA AHJKT AHMBA AI. AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AQUVI ASPBG AVWKF AZFZN AZQEC BCR BCU BEC BENPR BKEYQ BKNYI BLC BPHCQ BTJBQ BVXVI BZLQD C1A C45 CCPQU CGR CUY CVF DWQXO E3Z EBS ECM EIF EJD EMB EMOBN EX3 F5P FEDTE FYUFA G8K GNUQQ GUQSH H13 HMCUK HVGLF H~9 IH2 J5H K-O K9- L7B LPU M0R M0T M1P M2O M5~ MV1 MVM N4W NAPCQ NPM OBH OCB OFXIZ OGEVE OHH OHT OVD OVIDX P2P PCD PQQKQ PROAC PSQYO Q2X RWL RXW S0X SJFOW SJN SV3 TAE TEORI TPH TR2 TWZ UKHRP UKR VH1 VVN WH7 WOQ WOW X6Y X7M XOL YFH YOC YQJ YYP ZGI ZXP ZY1 ~H1 |
ID | FETCH-LOGICAL-c194t-c872d260ab16dce4fb25aa79cc742b2d16db88e0177c30bbe849b912dabd5e12 |
ISSN | 0003-4819 |
IngestDate | Sat Sep 28 08:35:12 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c194t-c872d260ab16dce4fb25aa79cc742b2d16db88e0177c30bbe849b912dabd5e12 |
PMID | 6089632 |
ParticipantIDs | pubmed_primary_6089632 |
PublicationCentury | 1900 |
PublicationDate | 1984-Oct |
PublicationDateYYYYMMDD | 1984-10-01 |
PublicationDate_xml | – month: 10 year: 1984 text: 1984-Oct |
PublicationDecade | 1980 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Annals of internal medicine |
PublicationTitleAlternate | Ann Intern Med |
PublicationYear | 1984 |
SSID | ssj0003828 |
Score | 1.4894662 |
Snippet | Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 447 |
SubjectTerms | Adult Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Blood Cell Count Carmustine - administration & dosage Carmustine - adverse effects Clinical Trials as Topic Combined Modality Therapy Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Female Gastrointestinal Diseases - chemically induced Hematologic Diseases - chemically induced Hodgkin Disease - drug therapy Hodgkin Disease - pathology Humans Male Mechlorethamine - administration & dosage Mechlorethamine - adverse effects Neoplasm Staging Peripheral Nervous System Diseases - chemically induced Prednisone - administration & dosage Prednisone - adverse effects Procarbazine - administration & dosage Procarbazine - adverse effects Random Allocation Vinblastine - administration & dosage Vinblastine - adverse effects Vincristine - administration & dosage Vincristine - adverse effects |
Title | BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/6089632 |
Volume | 101 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1La9tAEICXJKUll9JXSJ_ModCDo9SSVtaqt9SkNQEnobglt7C7WgVT2zKxXUr_a_9LZ_YhGSelj4sx0rJeez6PZmfnwdjrKtOKZyllt0sV8diISKmqispupaVOlOnZ3KrhaW_wmZ9cZBdb2ztrUUurpTrUP27NK_kfqeI1lCtlyf6DZJtJ8QK-R_niK0oYX_9Kxu_7X87PO_izT30elYu-bM71B3V5Zdtt5YtwEmM78fhOonbwFVmN1CZ8dd1YjzbOHK3pzjV1gyN_GkkijFysUL18s40C7NHDhJTlsv4-1mTRkyveZ8x1hme4PGr9MDWzQzopWE1c6AhZu8fS1mhAjVTPja8_fjbTriaU85G1tW9vlHseO0_m5GZwgPxqpmbsWzq3gctHNovHfZOTNkyyT0ku_vypcTd9qhc-D-hj6xWJC8Gb-LpW06cRF14dB03fjmj9GFZvc1f2c_N5kqe2A2YzGX4K7rijjdEoufnUItbrClRoyR9vbpT49ne22XYuSFefksfJWxOpSETo-khLcJWzaGFvb1nWLrvrJ9vYJllzafSA3ff7HDhy0D5kW2b2iN0bemE9Zj8tu7DOLiCOENgFz-6bBXhy30Hg1g70NELgFuoKArfQcHvQjAvUHgAyC8QsBGaBmAViFiQQsxCYBc8sTY6rBM8srDELgVmwzIJl9gkbfTge9QeRbzUS6bjgy0iLPClxay9V3Cu14ZVKMinzQuucJyop8aoSwuDjK9dpVykjeKGKOCmlKjMTJ3tsZ1bPzD6DuEq6ZcYLyUWXV3Eu89homZVFrFOOj8enbM_J5XLuyslceoE9-92N52y3JfwFu1PhH828RFN4qV5ZVn4BdoO5bw |
link.rule.ids | 783 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=BCVPP+chemotherapy+for+advanced+Hodgkin%27s+disease%3A+evidence+for+greater+duration+of+complete+remission%2C+greater+survival%2C+and+less+toxicity+than+with+a+MOPP+regimen.+Results+of+the+Eastern+Cooperative+Oncology+Group+study&rft.jtitle=Annals+of+internal+medicine&rft.au=Bakemeier%2C+R+F&rft.au=Anderson%2C+J+R&rft.au=Costello%2C+W&rft.au=Rosner%2C+G&rft.date=1984-10-01&rft.issn=0003-4819&rft.volume=101&rft.issue=4&rft.spage=447&rft_id=info:doi/10.7326%2F0003-4819-101-4-447&rft_id=info%3Apmid%2F6089632&rft_id=info%3Apmid%2F6089632&rft.externalDocID=6089632 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4819&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4819&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4819&client=summon |